Literature DB >> 35245456

Kynurenine importation by SLC7A11 propagates anti-ferroptotic signaling.

Alessandra Fiore1, Leonie Zeitler1, Marion Russier1, Annette Groß1, Maria-Kathrin Hiller1, Joanne L Parker2, Luca Stier1, Thomas Köcher3, Simon Newstead2, Peter J Murray4.   

Abstract

IDO1 oxidizes tryptophan (TRP) to generate kynurenine (KYN), the substrate for 1-carbon and NAD metabolism, and is implicated in pro-cancer pathophysiology and infection biology. However, the mechanistic relationships between IDO1 in amino acid depletion versus product generation have remained a longstanding mystery. We found an unrecognized link between IDO1 and cell survival mediated by KYN that serves as the source for molecules that inhibit ferroptotic cell death. We show that this effect requires KYN export from IDO1-expressing cells, which is then available for non-IDO1-expressing cells via SLC7A11, the central transporter involved in ferroptosis suppression. Whether inside the "producer" IDO1+ cell or the "receiver" cell, KYN is converted into downstream metabolites, suppressing ferroptosis by ROS scavenging and activating an NRF2-dependent, AHR-independent cell-protective pathway, including SLC7A11, propagating anti-ferroptotic signaling. IDO1, therefore, controls a multi-pronged protection pathway from ferroptotic cell death, underscoring the need to re-evaluate the use of IDO1 inhibitors in cancer treatment.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GCN2; IDO1; NRF2; SLC7A11; cancer; ferroptosis; kynurenine; metabolism; tryptophan

Mesh:

Substances:

Year:  2022        PMID: 35245456     DOI: 10.1016/j.molcel.2022.02.007

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  3 in total

1.  Puerarin Induces Molecular Details of Ferroptosis-Associated Anti-Inflammatory on RAW264.7 Macrophages.

Authors:  Jinzi Zeng; Ning Zhao; Jiajia Yang; Weiyang Kuang; Xuewei Xia; Xiaodan Chen; Zhiyuan Liu; Riming Huang
Journal:  Metabolites       Date:  2022-07-15

Review 2.  Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy.

Authors:  Francesco De Sanctis; Annalisa Adamo; Stefania Canè; Stefano Ugel
Journal:  Semin Immunopathol       Date:  2022-09-26       Impact factor: 11.759

3.  Comprehensive analysis of ferroptosis-related gene signatures as a potential therapeutic target for acute myeloid leukemia: A bioinformatics analysis and experimental verification.

Authors:  Zhiyuan Zheng; Xiaoying Hong; Xiaoxue Huang; Xiandong Jiang; He Jiang; Yingying Huang; Wei Wu; Yan Xue; Donghong Lin
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.